A new trading day began on Tuesday, with Nurix Therapeutics Inc (NASDAQ: NRIX) stock price down -3.94% from the previous day of trading, before settling in for the closing price of $28.14. NRIX’s price has ranged from $4.96 to $29.56 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 27.29% over the past five years. Meanwhile, its annual earnings per share averaged -5.33%. With a float of $69.64 million, this company’s outstanding shares have now reached $70.84 million.
Let’s look at the performance matrix of the company that is accounted for 284 employees. In terms of profitability, gross margin is 71.85%, operating margin of -343.3%, and the pretax margin is -313.19%.
Nurix Therapeutics Inc (NRIX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 1.69%, while institutional ownership is 93.95%. The most recent insider transaction that took place on Nov 04 ’24, was worth 82,250. In this transaction Chief Legal Officer of this company sold 3,290 shares at a rate of $25.00, taking the stock ownership to the 28,084 shares. Before that another transaction happened on Nov 04 ’24, when Company’s Officer proposed sale 3,290 for $24.47, making the entire transaction worth $80,506.
Nurix Therapeutics Inc (NRIX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -5.33% per share during the next fiscal year.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Here are Nurix Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 33.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.91, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.67 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc (NASDAQ: NRIX) saw its 5-day average volume 1.62 million, a positive change from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 70.90%. Additionally, its Average True Range was 1.46.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 78.80%, which indicates a significant increase from 58.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.75% in the past 14 days, which was lower than the 53.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.45, while its 200-day Moving Average is $18.41. Nevertheless, the first resistance level for the watch stands at $27.99 in the near term. At $28.96, the stock is likely to face the second major resistance level. The third major resistance level sits at $29.71. If the price goes on to break the first support level at $26.27, it is likely to go to the next support level at $25.52. The third support level lies at $24.55 if the price breaches the second support level.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
With a market capitalization of 1.91 billion, the company has a total of 70,836K Shares Outstanding. Currently, annual sales are 76,990 K while annual income is -143,950 K. The company’s previous quarter sales were 12,590 K while its latest quarter income was -48,960 K.
